Form 4: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management has disclosed the sale of 678,226 shares of Werewolf Therapeutics (HOWL) across three days in June 2026.

Summary

• RA Capital Management, L.P. and associated entities sold a total of 678,226 shares of Werewolf Therapeutics common stock.
• The sales occurred between June 9, 2026, and June 11, 2026.
• Shares were sold at weighted average prices ranging from $0.37 to $0.38 per share.
• Following these transactions, the reporting persons maintain a beneficial ownership of 5,437,914 shares across two funds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as bearish, as the exit of a major institutional investor at low price points often signals a lack of conviction in the near-term upside of the stock.

Positives

• The divestment provides liquidity to the reporting funds.

Negatives

• Significant reduction in equity position by a major 10% institutional shareholder.
• Sales executed at low price points, reflecting downward pressure on the stock.

Risks

• Continued selling pressure from major institutional holders can negatively impact share price volatility.
• The low trading price (sub-$0.40) may indicate challenges in the company's market valuation or capital position.

Future Outlook

No specific forward-looking guidance regarding the company's operations was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotech firms often signals a rebalancing of portfolio risk or a lack of confidence in near-term clinical catalysts, particularly when shares are trading at distressed levels.

Comparison to Industry Standards

• The sale of shares by a 10% owner is a standard regulatory disclosure and does not necessarily reflect the company's internal operational performance.
• The price point of $0.37-$0.38 is significantly lower than typical biotech valuations, suggesting the company is currently trading as a micro-cap or distressed asset.

Stakeholder Impact

• Shareholders may experience increased price volatility due to the institutional sell-off.
• The reduction in ownership by a major backer may influence market sentiment regarding the company's long-term prospects.

Next Steps

• Continued monitoring of Form 4 filings to determine if RA Capital intends to further reduce or exit their position.

Key Dates

Recommendation

The exit of a major institutional investor at sub-dollar price levels is a negative signal that often precedes further downward pressure or a lack of institutional support for the stock.

Keywords

Werewolf Therapeutics, HOWL, RA Capital Management, Insider Selling, Form 4, Biotech, Equity Divestment